Venous Thromboembolism Market is Expected to Expand at a Healthy Growth Rate by 2030 | Key Companies – Ionis, Bayer, Bristol-Myers Squibb, Janssen, Quercis, Ono Pharma, Verseon, and Others

Venous Thromboembolism Market is Expected to Expand at a Healthy Growth Rate by 2030 | Key Companies - Ionis, Bayer, Bristol-Myers Squibb, Janssen, Quercis, Ono Pharma, Verseon, and Others

“Delveinsight Business Research LLP”
DelveInsight’s “Venous Thromboembolism Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Venous Thromboembolism Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Venous Thromboembolism market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Venous Thromboembolism Market

Venous Thromboembolism: An Overview

Venous Thromboembolism (VTE) is a disorder that includes Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) . A deep vein thrombosis (DVT) occurs when a blood clot forms in a deep vein, usually in the lower leg, thigh, or pelvis. A deep vein thrombosis may occur if the flow of blood slows down in the body’s deep veins. A pulmonary embolism (PE) occurs when a clot breaks loose and travels through the bloodstream to the lungs.

Venous Thromboembolism Market Key Facts

  • “Incidence, Characteristics and Management of Venous Thromboembolism in Japan During 2011,” by Ota et al., (2015), found that 16,096 and 24,538 individuals in Japan were diagnosed with new PE and DVT, respectively, during 2011, which represented overall annual incidences of 12.6 and 19.2 per 100,000, respectively.

  • As per the research study of Palo et al. (2018), Thromboembolism has a significant impact on morbidity and mortality internationally. A multinational report of European Union countries estimated that the total number of symptomatic, nonfatal VTE events per annum was more than 465,000 cases of DVT and more than 295,000 cases of PE. 

Get FREE sample copy at: Venous Thromboembolism Therapeutics Market

Key Benefits of Venous Thromboembolism Market Report

  • The report provides an in-depth analysis of Venous Thromboembolism Market Size and Share till 2030 in the seven major markets.

  • The report will help in developing business strategies by understanding the Venous Thromboembolism Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.

  • It covers Venous Thromboembolism current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

  • The report provides a detailed assessment of the Venous Thromboembolism market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Venous Thromboembolism Market

The Venous Thromboembolism market is expected to grow in the coming years owing to the expected launch of new therapies, extensive research and development activities of pharmaceutical companies, increased patient pool, improvement in the diagnosis rate owing to guidelines recommendations and government initiatives.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Venous Thromboembolism market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Venous Thromboembolism market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Venous Thromboembolism Epidemiology

The epidemiology section covers insights about the historical and current Venous Thromboembolism patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Venous Thromboembolism Epidemiology Segmentation

  • Total Incident Cases 

  • Total Diagnosed Cases 

  • Type-specific Cases 

  • Total Age-specific Cases 

  • Occurrence-specific Cases 

  • Total Prophylactic/Preventive Setting Cases 

  • Total Potential (Mortality and Recurrent adjusted) Cases 

  • Total Treated Cases of VTE for Treatment and Prophylactic Settings

Venous Thromboembolism Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Venous Thromboembolism market or expected to get launched in the market during the study period. The analysis covers Venous Thromboembolism market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Venous Thromboembolism Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Venous Thromboembolism Therapeutics Analysis

The dynamics of the Venous Thromboembolism market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world.

Key Companies in the Venous Thromboembolism Market includes:

  • Ionis Pharmaceuticals

  • Bayer Pharmaceuticals

  • Bristol-Myers Squibb 

  • Janssen Pharmaceuticals

  • Quercis Pharmaceuticals

  • Ono Pharmaceutical

  • Verseon Corporation

  • Bayer Pharmaceuticals

And several others.

Venous Thromboembolism Therapies covered in the report includes:

  • ONO-7684

  • Milvexian

  • Isoquercetin

  • VE-1902


  • Osocimab (BAY 1213790) 

And many others.

Request for Sample @ Venous Thromboembolism Emerging Therapies and Key Companies

Table of Content

1. Key Insights

2. Executive Summary 

3. Venous Thromboembolism Competitive Intelligence Analysis

4. Venous Thromboembolism Market Overview at a Glance

5. Venous Thromboembolism Disease Background and Overview

6. Venous Thromboembolism Patient Journey

7. Venous Thromboembolism Epidemiology and Patient Population

8. Venous Thromboembolism Treatment Algorithm, Current Treatment, and Medical Practices

9. Venous Thromboembolism Unmet Needs

10. Key Endpoints of Venous Thromboembolism Treatment

11. Venous Thromboembolism Marketed Products

12. Venous Thromboembolism Emerging Therapies

13. Venous Thromboembolism Seven Major Market Analysis

14. Attribute Analysis

15. Venous Thromboembolism Market Outlook (7 major markets)

16. Venous Thromboembolism Access and Reimbursement Overview

17. KOL Views on the Venous Thromboembolism Market.

18. Venous Thromboembolism Market Drivers

19. Venous Thromboembolism Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States